Roche secures ALK7 license. Roche Holding stock costs EUR 407.60

Published on 10/16/2026 at 10:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rona grants Roche an ALK7 license with USD 100 million upfront. Roche Holding stock costs EUR 407.60 on October 16 before October 22 sales.

License and reporting dates

Rona granted Roche an ALK7 license with up to USD 100 million in upfront and near-term payments on October 13, 2026.
Roche will publish third-quarter sales on October 22, 2026.
Roche Holding stock was trading at EUR 407.60 at 10:33 a.m. CEST at Lang & Schwarz on October 16, 2026.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (ISIN CH1499059983) was trading at EUR 407.60 at Lang & Schwarz on October 16, 2026, as the pharmaceutical group advances an obesity drug partnership. PR Newswire reported on October 13, 2026, that Rona Therapeutics granted Roche an exclusive worldwide license for an investigational RNA interference candidate targeting ALK7.

Obesity deal adds pipeline depth

The agreement covers upfront and near-term milestone payments of up to USD 100 million for Rona, followed by as much as USD 1.06 billion in potential development, regulatory and commercial milestones, plus tiered royalties on global net sales. The candidate uses Rona's extrahepatic delivery platform and targets a protein expressed mainly in fat cells.

The commercial value is conditional rather than guaranteed. Roche gains worldwide development and commercialization rights, while the program still depends on clinical, regulatory and commercial progress.

What do the targets imply?

Analyst views remain divided ahead of the next sales update. According to FinanzNachrichten on October 12, 2026, Jefferies raised its Roche target from CHF 230.00 to CHF 250.00 but kept an Underperform rating. The same report cited a 40.00 percent valuation premium and identified Giredestrant and Fenebrutinib as important future tests.

Three recent Roche milestones

On October 9, 2026, Jefferies raised its target from CHF 230.00 to CHF 250.00; on October 13, 2026, Rona granted Roche worldwide ALK7 rights with up to USD 1.06 billion in potential milestones; on October 15, 2026, Roche confirmed its third-quarter sales presentation for October 22, 2026. The first two events carry source support from FinanzNachrichten and PR Newswire.

Upcoming reporting dates

Roche says third-quarter sales will be published on October 22, 2026, before the Swiss exchange opens, with a presentation from 2:00 p.m. to 3:30 p.m. CEST. The investor calendar also lists a Berenberg Pharma CFO Series event for November 2, 2026.

Stock quote in the Swiss context

Roche Holding AG operates across pharmaceuticals and diagnostics, with oncology, neuroscience, immunology and metabolic disease among its areas of activity. Its primary listing is on SIX Swiss Exchange, while the euro quotation gives German investors a separate trading reference.

Roche Holding stock was trading at EUR 407.60 at Lang & Schwarz on October 16, 2026 at 10:33 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.